These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30444134)

  • 21. Fibrosis and the intestinal microbiome; a focus on chronic liver disease.
    Beraza N
    Curr Opin Pharmacol; 2019 Dec; 49():76-81. PubMed ID: 31670055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of the Intestinal Microbiome in Cholestatic Liver Disease.
    LaRusso NF; Tabibian JH; O'Hara SP
    Dig Dis; 2017; 35(3):166-168. PubMed ID: 28249266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting Dysbiosis for the Treatment of Liver Disease.
    Anand G; Zarrinpar A; Loomba R
    Semin Liver Dis; 2016 Feb; 36(1):37-47. PubMed ID: 26870931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gut microbiota and liver diseases.
    Minemura M; Shimizu Y
    World J Gastroenterol; 2015 Feb; 21(6):1691-702. PubMed ID: 25684933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation].
    Aitbaev KA; Murkamilov IT; Fomin VV
    Ter Arkh; 2017; 89(8):120-128. PubMed ID: 28914862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?
    Brandl K; Schnabl B
    Expert Rev Gastroenterol Hepatol; 2015; 9(8):1069-76. PubMed ID: 26088524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microbiome alterations observed in liver diseases present opportunities for potential fecal transplantation.
    Heath RD; Mir F; Ibdah JA; Tahan V
    Turk J Gastroenterol; 2016 Nov; 27(6):495-498. PubMed ID: 27852539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Should we do a liver puncture biopsy in patients with chronic "unexplained" cytolyses?].
    De Lédinghen V
    Gastroenterol Clin Biol; 2002; 26(8-9):724-7. PubMed ID: 12434076
    [No Abstract]   [Full Text] [Related]  

  • 29. Gut Microbiota and Complications of Liver Disease.
    Acharya C; Bajaj JS
    Gastroenterol Clin North Am; 2017 Mar; 46(1):155-169. PubMed ID: 28164848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the microbiota in the management of gastrointestinal and liver disease.
    Quigley EM; Monsour HP
    Rev Gastroenterol Peru; 2013; 33(2):139-44. PubMed ID: 23838941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alcoholic liver disease: the gut microbiome and liver cross talk.
    Hartmann P; Seebauer CT; Schnabl B
    Alcohol Clin Exp Res; 2015 May; 39(5):763-75. PubMed ID: 25872593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of Gut Microbiota in Liver Disease.
    Brenner DA; Paik YH; Schnabl B
    J Clin Gastroenterol; 2015; 49 Suppl 1(0 1):S25-7. PubMed ID: 26447960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Differentiation of Intestinal-Failure-Associated Liver Disease from Nonalcoholic Fatty Liver and Nonalcoholic Steatohepatitis.
    Buchman AL; Naini BV; Spilker B
    Semin Liver Dis; 2017 Feb; 37(1):33-44. PubMed ID: 28201847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bifidobacterium pseudocatenulatum LI09 and Bifidobacterium catenulatum LI10 attenuate D-galactosamine-induced liver injury by modifying the gut microbiota.
    Fang D; Shi D; Lv L; Gu S; Wu W; Chen Y; Guo J; Li A; Hu X; Guo F; Ye J; Li Y; Li L
    Sci Rep; 2017 Aug; 7(1):8770. PubMed ID: 28821814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is there a role for probiotics in liver disease?
    Lo RS; Austin AS; Freeman JG
    ScientificWorldJournal; 2014; 2014():874768. PubMed ID: 25436233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The gut microbiota and host health: a new clinical frontier.
    Marchesi JR; Adams DH; Fava F; Hermes GD; Hirschfield GM; Hold G; Quraishi MN; Kinross J; Smidt H; Tuohy KM; Thomas LV; Zoetendal EG; Hart A
    Gut; 2016 Feb; 65(2):330-9. PubMed ID: 26338727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of Intestinal Fungi and Its Metabolites in Chronic Liver Diseases.
    You N; Zhuo L; Zhou J; Song Y; Shi J
    Gut Liver; 2020 May; 14(3):291-296. PubMed ID: 31554391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of the intestinal microbiome in liver fibrosis development and new treatment strategies.
    Zhou R; Fan X; Schnabl B
    Transl Res; 2019 Jul; 209():22-38. PubMed ID: 30853445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alterations in intestinal microbiota relate to intestinal failure-associated liver disease and central line infections.
    Wang P; Wang Y; Lu L; Yan W; Tao Y; Zhou K; Jia J; Cai W
    J Pediatr Surg; 2017 Aug; 52(8):1318-1326. PubMed ID: 28501098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.